Zavoral Miroslav, Suchanek Stepan, Majek Ondrej, Fric Premysl, Minarikova Petra, Minarik Marek, Seifert Bohumil, Dusek Ladislav
Miroslav Zavoral, Stepan Suchanek, Premysl Fric, Petra Minarikova, Department of Medicine, 1 Faculty of Medicine, Military University Hospital, Charles University, CZ 169 02 Prague, Czech Republic.
World J Gastroenterol. 2014 Apr 14;20(14):3825-34. doi: 10.3748/wjg.v20.i14.3825.
Colorectal cancer (CRC) is the second most common cancer in Europe and its incidence is steadily increasing. This trend could be reversed through timely secondary prevention (screening). In the last twenty years, CRC screening programs across Europe have experienced considerable improvements (fecal occult blood testing; transition from opportunistic to population based program settings). The Czech Republic is a typical example of a country with a long history of nationwide CRC screening programs in the face of very high CRC incidence and mortality rates. Each year, approximately 8000 people are diagnosed with CRC and some 4000 die from this malignancy. Twenty years ago, the first pilot studies on CRC screening led to the introduction of the opportunistic Czech National Colorectal Cancer Screening Program in 2000. Originally, this program was based on the guaiac fecal occult blood test (FOBT) offered by general practitioners, followed by colonoscopy in cases of FOBT positivity. The program has continuously evolved, namely with the implementation of immunochemical FOBTs and screening colonoscopy, as well as the involvement of gynecologists. Since the establishment of the Czech CRC Screening Registry in 2006, 2405850 FOBTs have been performed and 104565 preventive colonoscopies recorded within the screening program. The overall program expanded to cover 25.0% of the target population by 2011. However, stagnation in the annual number of performed FOBTs lately has led to switching to the option of a population-based program with personal invitation, which is currently being prepared.
结直肠癌(CRC)是欧洲第二常见的癌症,其发病率正在稳步上升。通过及时的二级预防(筛查),这种趋势可以得到扭转。在过去的二十年里,欧洲各地的CRC筛查项目有了显著改善(粪便潜血检测;从机会性筛查向基于人群的项目设置转变)。捷克共和国就是一个典型例子,面对极高的CRC发病率和死亡率,该国开展全国性CRC筛查项目已有很长历史。每年约有8000人被诊断为CRC,约4000人死于这种恶性肿瘤。二十年前,关于CRC筛查的首批试点研究促成了2000年机会性的捷克国家结直肠癌筛查项目的引入。最初,该项目基于全科医生提供的愈创木脂粪便潜血检测(FOBT),FOBT呈阳性的病例随后进行结肠镜检查。该项目不断发展,即实施了免疫化学FOBT和筛查结肠镜检查,以及妇科医生的参与。自2006年捷克CRC筛查登记处成立以来,在筛查项目中已进行了2405850次FOBT检测,并记录了104565例预防性结肠镜检查。到2011年,整个项目扩大到覆盖目标人群的25.0%。然而,最近每年进行的FOBT检测数量停滞不前,导致转向个人邀请的基于人群的项目选项,目前该项目正在筹备中。